SOURCE: Health Discovery Corporation

April 18, 2005 08:00 ET

Health Discovery Corporation Presents Revolutionary New Prostate Cancer Biomarker Discovery at the Molecular Medicine Tri-Conference 2005 in San Francisco

SAVANNAH, GA -- (MARKET WIRE) -- April 18, 2005 -- Health Discovery Corporation (OTC BB: HDVY) today announced that Dr. Isabelle Guyon would present the Company's latest prostate cancer biomarker discovery at the prestigious Molecular Medicine Tri-Conference 2005 on Tuesday, April 19th in San Francisco, California. The new biomarker discovery includes molecular patterns characteristic of zonal and histological tissue classification of the prostate. The presentation will include Health Discovery Corporation's promising new prostate cancer biomarkers that were recently validated in a study that demonstrated a 90% sensitivity and specificity on two completely independent data sets.

Dr. Thomas A. Stamey, who is Professor and Founding Chairman of the Department of Urology at Stanford University School of Medicine and currently holds the Thomas A. Stamey Endowed Research Chair in Urology at Stanford University School of Medicine, commented, "At this point in time when the PSA has been shown to be ineffective in identifying clinically significant prostate cancer, Health Discovery Corporation's recent biomarker discovery creating a genomic based test that separates grade 4/5 prostate cancer, the most malignant and clinically significant type of prostate cancer from BPH (benign prostatic hypertrophy) and normal prostate with a very high degree of accuracy is an exciting and outstanding accomplishment." Dr. Stamey continued, "Dr. Isabelle Guyon, who lead the scientific team to this remarkable discovery for Health Discovery Corporation, is truly to be commended for a brilliant mathematical result and a job well done!"

Dr. Isabelle Guyon, who will be presenting the prostate cancer discovery for Health Discovery Corporation, added: "Many past attempts at merging datasets from heterogeneous sources have failed. But, we have overcome some of the major hurdles that prevented us from doing this. Our results are unprecedented and prove the maturity of the microarray technology, the quality of our data, the power of our analytical methods, and, even more importantly, the existence of many promising biomarkers and drug targets for prostate cancer."

Dr. Herbert Fritsche, Professor and Director of Clinical Chemistry at MD Anderson Cancer Center, commented: "Current serum PSA based prostate cancer detection strategies result in an unacceptable high false positive rate, leading to many unnecessary biopsies and the over-diagnosis of clinically insignificant prostate cancer. This results in the surgical removal of the prostate in men who may not actually need this major surgical procedure, often leaving them impotent and incontinent." Dr. Fritsche continued, "There is therefore a critical need for a PSA replacement that can accurately discriminate between latent, non-aggressive prostate cancer and clinically significant prostate cancer. Health Discovery Corporation has discovered and now validated promising prostate cancer biomarkers that have been shown to identify these very important clinically significant cancers. In addition, the Company found promising diagnostic markers and new drug targets for BPH (benign prostatic hypertrophy). I am very excited about moving to the next step and using the gene products of this discovery to develop a new blood test for prostate cancer."

Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation, stated: "I am very proud of the Scientific Team at Health Discovery Corporation, lead by Dr. Isabelle Guyon, for this remarkable discovery which has now been validated in two completely independent data sets." Dr. Barnhill continued, "We have patent-protected these biomarkers and now look forward to completing the process of clinical validation and commercialization of this revolutionary new test!"

Health Discovery Corporation is a systems biology-oriented biomarker and pathway discovery company, which provides all aspects of First-Phase Biomarker Discovery(SM). The Company was established to provide pharmaceutical and diagnostic companies worldwide with newly discovered biomarkers used to create more accurate diagnostic tests, novel drug targets for more personalized medicines and new methods for detecting patients "at-risk" for toxicity-related events, thereby providing safer medications. Founded in September 2003, the Company is headquartered in Savannah, GA.

This news release contains "forward-looking statements" within the meaning of Section 27A of the Securities Acts of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct.

Contact Information